Cytomegalovirus and Varicella–Zoster Virus Vaccines
Molecular Biology of Specific Diseases
Published Online: 15 SEP 2006
Copyright © 2006 Wiley-VCH Verlag GmbH & Co. KGaA. All rights reserved.
Reviews in Cell Biology and Molecular Medicine
How to Cite
Hunt, L. A. 2006. Cytomegalovirus and Varicella–Zoster Virus Vaccines. Reviews in Cell Biology and Molecular Medicine. .
- Published Online: 15 SEP 2006
Classical live-attenuated vaccines were developed several decades ago for two clinically important human herpesviruses, varicella-zoster virus and human cytomegalovirus. The varicella vaccine has been licensed for immunization of normal children in Japan, Korea, and the United States for a number of years. In contrast, live-attenuated cytomegalovirus has only been tested in a limited number of studies of organ transplant recipients and healthy adult volunteers, and has not yet been considered for licensure. A number of experimental cytomegalovirus vaccines have been developed using molecular biology and recombinant DNA technology, because of theoretical concerns about the long-term safety and effectiveness of the currently available live cytomegalovirus vaccines. Some of the same techniques are also being applied to varicella-zoster virus to develop improved vaccines that could supplement or replace the current varicella vaccine or provide protection against viral reactivation and zoster. The major emphasis of high-technology vaccine development has been on the viral glycoproteins because they are the targets of neutralizing antibody, and includes both recombinant protein subunit vaccines and live-recombinant virus vaccines. Other virion and nonstructural viral proteins are also being considered as immunogens for cytotoxic T-cell responses.
- Live Vaccine;
- Neutralizing Antibody;
- Seropositive versus Seronegative;
- Structural versus Nonstructural Protein;
- Subunit Vaccine;